Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2739 - Cardiotoxic effects of the novel anti-ErbB2 agent ado trastuzumab emtansine


10 Oct 2016


Poster display


Rosario Iaffaioli


Annals of Oncology (2016) 27 (6): 1-14. 10.1093/annonc/mdw362


R.V. Iaffaioli1, C. Coppola2, G. Piscopo2, G. Riccio2, A. Rienzo2, C. Maurea2, A. Barbieri3, C. De Lorenzo4, N. Maurea2

Author affiliations

  • 1 Dipartimento Di Oncologia Addominale, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 2 Cardiology, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 3 Animal Facility, Istituto Nazionale Tumori – I.R.C.C.S - Fondazione Pascale, 80131 - Napoli/IT
  • 4 Department Of Molecular Medicine And Medical Biotechnology, University ‘Federico II’, Napoli/IT


Abstract 2739


Ado trastuzumab emtansine (TDM1) is a novel antibody–drug conjugate consisting of trastuzumab (TRAS) covalently linked to the highly potent microtubule inhibitory agent DM1 via a stable thioether linker. TDM1 is used in metastatic ErbB2 positive breast cancer patients, previously treated with TRAS and taxane. Although the potential cardiotoxic effects of T-DM1 have not yet been fully elucidated, they can include all the mechanisms of TRAS-related cardiotoxicity, such as blockade of ErbB2,PI3K-Akt and MAPK pathways. Furthermore, since TDM1 is also used in combination with other anti-ErbB2 agents, the risk of cardiotoxic side effects could be further increased. Here, we aim to assess the cardiotoxic side effects of TDM1 in vitro and in vivo.


To evaluate the cardiotoxic effects of TDM1 in vitro, human fetal cardiomyocytes (HFC) and cardiomyoblasts (H9C2) were treated, for 3 days, in the absence or in the presence of increasing concentrations of TDM1 and TRAS. Moreover, to assess the cardiac function in vivo, C57/BL6 mice, 2-4 months old, were daily treated with TDM1 (44.4 mg/kg/day). At day 0 and after 7 days, fractional shortening (FS) and ejection fraction (EF) were measured, by M/B mode echocardiography, and radial and longitudinal strain (RS and LS) were evaluated using 2D speckle-stracking.


TDM1 shows a higher toxicity on HFC and H9C2 cells with respect to TRAS. TDM1 clearly causes more marked changes in HFC cell morphology, cells, that indeed lost their typical features to assume distorted forms (rounded-shape). In in vivo studies: after 7 days with TDM1, FS decreased to 53.6 ± 0.9 %, versus 61.0 ± 0.8 % (sham), (p 


Here we show for the first time the cardiotoxic effects of TDM1, both in in vitro, and in vivo models.

Clinical trial identification

Legal entity responsible for the study



Fondi di Ricerca Corrente destinati all' Istituto Nazionale Tumori Pascale - Napoli


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings